RDEA3170 2.5 mg

DRUG2 trials

Sponsors

Ardea Biosciences, Inc.

Conditions

Gout

Phase 1

RDEA3170 Bioavailability Study

CompletedNCT02336594

Ardea Biosciences, Inc.Gout

Start: 2014-11-30End: 2015-03-31Updated: 2017-10-13

Phase 2

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

CompletedNCT02498652

Ardea Biosciences, Inc.Gout

Start: 2015-07-28End: 2016-06-02Updated: 2018-01-23

Related Papers

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

RMD Open2018-02-0139 citations